Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Natural History of the Leukodystrophies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02843555
Recruitment Status : Completed
First Posted : July 26, 2016
Last Update Posted : March 22, 2019
Sponsor:
Information provided by (Responsible Party):
Baylor Research Institute

Brief Summary:

The purpose of this study is to:

  1. define novel homogeneous groups of patients with LDs and
  2. work toward finding the cause of these disorders.

Condition or disease
Leukodystrophies

Detailed Description:
Patients with leukodystrophies (LDs) of unknown etiology are a heterogeneous group but constitute the second largest group of genetic white matter diseases. In order to find the cause of leukodystrophies, patients with LDs of unknown cause will be analyzed clinically, neurophysiologically, biochemically and genetically. Patients would have been diagnosed as having no known leukodystrophies at outside centers. At the Baylor University Medical Center, such patients will undergo a series of neuropsychological, blood, urine, spinal fluid, radiological, and peripheral tissue pathological tests. Some of these tests will be part of a standard battery while others will be tailored to individual patients. Patients will be followed yearly or as necessary. Patients will be screened for mutations in genes coding for structural myelin proteins. In some patients in whom all tests yielded no information regarding the etiology of their disease, and in whom there is evidence to suggest involvement of the peripheral nervous system, a sural nerve biopsy will be considered. Sural nerve biopsy tissue will be evaluated using a novel combination of approaches including detailed pathological, immunohistochemical, and biochemical analysis of myelin proteins and lipids. Schwann cell biology and expression of myelin genes in the brain will also be investigated in situ. It is hoped that the present study will help clarify the nosology of the leukodystrophies and significantly advance our understanding of the pathogenesis of these diseases.

Layout table for study information
Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Etiology, Pathogenesis, and Natural History of the Leukodystrophies
Actual Study Start Date : January 23, 2019
Actual Primary Completion Date : January 23, 2019
Actual Study Completion Date : January 23, 2019

Resource links provided by the National Library of Medicine


Group/Cohort
Leukodystrophy of unknown etiology
Subjects who may have an undiagnosed form of leukodystrophy



Primary Outcome Measures :
  1. Neuropsychological evaluation to measure baseline cognitive function and detect signs of dementia over time [ Time Frame: Every 52 weeks up to 5 years ]
    Neuropsychological status is evaluated at Baseline and no less than once every year for the duration of the study to assess for any deterioration in function


Secondary Outcome Measures :
  1. Evoked potentials to assess involvement of different areas of brain over time [ Time Frame: Every 52 weeks up to 5 years ]
    Evoked potentials are evaluated at Baseline and no less than once every year for the duration of the study to assess for changes in function

  2. MRI of the brain to assess involvement of different areas of the brain over time [ Time Frame: Every 52 weeks ]
    Changes in the brain are assessed at Baseline and no less than once every year for the duration of the study to assess for changes

  3. Electroencephalogram to assess involvement of different areas of the brain over time [ Time Frame: Every 52 weeks up to 5 years ]
    EEG is assessed at Baseline and no less than once a year for the duration of the study to assess for changes in function

  4. Electromyelogram to assess for changes in muscle function over time [ Time Frame: Every 52 weeks up to 5 years ]
    EMG is assessed at Baseline and no less than once a year for the duration of the study to assess for changes in function

  5. Nerve Conduction study to assess abnormalities in affected nerves [ Time Frame: Every 52 weeks up to 5 years ]
    Nerve conduction is assessed at Baseline and no less than once a year for the duration of the study to assess for changes in function

  6. Skin biopsy for to look for evidence of storage disease [ Time Frame: Baseline ]
  7. DNA Studies to search for mutations in genes of structural myelin proteins or genes that control myelin production [ Time Frame: Baseline ]
  8. Spinal Tap to look for diagnostic markers of leukodystrophy [ Time Frame: Baseline ]
  9. Nerve Biopsy to look for pathological abnormalities in affected nerves [ Time Frame: Baseline ]
  10. Neuro-ophthalmological exam to assess for abnormalities in the eye [ Time Frame: Every 52 weeks up to 5 years ]
    Eyes are assessed at Baseline and no less than once a year for the duration of the study to assess for changes in function


Biospecimen Retention:   Samples With DNA
Blood, urine, skin


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects identified with a leukodystrophy of unknown etiology
Criteria

Inclusion Criteria:

Subjects must:

  • have clinical and radiographic signs of leukodystrophy without a specific etiology
  • no diagnosis of adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic leukodystrophy, Krabbe disease, Canavan disease, a well-defined amino acid organic acid disorder, or a systemic mitochondrial cytopathy.
  • First-degree relatives of patients with leukodystrophies of unknown etiology (father, mother, siblings, or sons and daughters of the patients)
  • Be able to travel to Baylor University Medical Center in Dallas Texas for evaluation and spend 5-8 working days on site
  • Be able to tolerate a general exam and neurological exam
  • Be able to tolerate a modest amount of blood drawing, provide a urine specimen, and have a skin biopsy(if not previously done)
  • Be able to tolerate the performance of necessary neuroimaging studies to include EEG and Head MRI
  • Be able to tolerate a neuropsychological testing and rehabilitation evaluation
  • Be able to tolerate spinal tap or nerve biopsy if needed

Exclusion Criteria:

  • Unable to travel to Baylor University Medical Center in Dallas Texas for evaluation
  • Refusal to sign a study consent form
  • Unable to tolerate the performance of the required testing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02843555


Locations
Layout table for location information
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Baylor Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Raphael Schiffmann, MD, MHS Baylor University Medical Center, Baylor Institute of Metabolic Disease
Layout table for additonal information
Responsible Party: Baylor Research Institute
ClinicalTrials.gov Identifier: NCT02843555    
Other Study ID Numbers: 008-169
First Posted: July 26, 2016    Key Record Dates
Last Update Posted: March 22, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Baylor Research Institute:
Leukodystrophy
Myelin Gene
Myelin Protein
Sural Nerve Biopsy
Undiagnosed Disease
Schwann Cell
White Matter Pathology
Motor Delay
Cognitive Regression
Motor Deterioration
Unknown Disease